Phase 2 Macular Degeneration Trial, Recruiting (NCT06467344)

Phase 2 Macular Degeneration Trial, Recruiting NCT06467344 Sponsor: Ascidian Therapeutics, Inc Condition: Macular Degeneration

Printed from Voxsanity (voxsanity.com.au) — NCT06467344 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Macular Degeneration

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who have a mutation (change) in a gene called ABCA4
People diagnosed with an ABCA4-related eye condition, specifically Stargardt disease type 1 or cone-rod dystrophy
People who have an area of damaged or lost tissue (atrophy) in the central part of the eye being studied (the macula)
People whose vision in the study eye is 20/50 or worse, meaning vision is significantly reduced

Who may not be able to join:

People whose cone-rod dystrophy or Stargardt-like condition is caused by mutations in other genes, not ABCA4
People who have a retinal (eye) disease that is not related to the ABCA4 gene
People who have a health condition — physical, mental, or related to substance use — or test results that the lead doctor and trial sponsor believe could affect safety, attendance at study visits, or the accuracy of the study results (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Alia Rashid, Ascidian Therapeutics

Phone: 207-573-0412

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06467344

Sponsor: Ascidian Therapeutics, Inc

Phase: Phase 2

Status: Recruiting

Condition: Macular Degeneration

Trial contact: 207-573-0412

More information: https://clinicaltrials.gov/study/NCT06467344

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who have a mutation (change) in a gene called ABCA4
People diagnosed with an ABCA4-related eye condition, specifically Stargardt disease type 1 or cone-rod dystrophy
People who have an area of damaged or lost tissue (atrophy) in the central part of the eye being studied (the macula)
People whose vision in the study eye is 20/50 or worse, meaning vision is significantly reduced

Who may not be able to join:

People whose cone-rod dystrophy or Stargardt-like condition is caused by mutations in other genes, not ABCA4
People who have a retinal (eye) disease that is not related to the ABCA4 gene
People who have a health condition — physical, mental, or related to substance use — or test results that the lead doctor and trial sponsor believe could affect safety, attendance at study visits, or the accuracy of the study results (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 2

Sponsor

Ascidian Therapeutics, Inc

Registry

ClinicalTrials.gov

Start date

11 June 2024

Est. completion

1 August 2030

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Safety and tolerability of ACDN-01 as measured by the number and severity of adverse events and serious adverse events.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov